Live Feeds
● TRACKER Updated 25d ago Β· 30 sources tracked

Merck licenses a KRAS G12D inhibitor for $400M upfront

Merck secured global rights to preclinical oral KRAS G12D inhibitor SPR2015 through an exclusive licensing agreement with SciBrunch Therapeutics, a Shanghai small-molecule RAS startup. The deal includes a $400 million upfront payment and potential milestone payments up to $2.13 billion. The asset is a preclinical KRAS G12D(ON) molecular glue that has not yet been tested in humans.

πŸŽ™οΈ

Listen to Live Briefing

Real-time synthesized voice briefing Β· Live Feeds Desk

⏱ ~2 min
Speed:
RSS Source map (30)
⚑ Key Developments & Real-Time Context
Text size:
  • βœ“ Merck agreed to a $400 million upfront payment for the licensing deal.
  • βœ“ The licensing agreement with SciBrunch Therapeutics includes potential milestone payments up to $2.13 billion.
  • βœ“ Roche agreed to acquire Carmot Therapeutics for $2.7 billion upfront.
  • βœ“ Carmot Therapeutics' pipeline includes three clinical-stage programmes.
πŸ›‘οΈ Source Corroboration: 30 independent reporting domains (90% confidence) ⏱ Read time: ~2 min

What changed

No new developments on the Merck licensing deal were reported; however, recent high-profile transactions in the pharmaceutical industry were disclosed.

Live updates

  1. Merck licenses KRAS G12D inhibitor for $400M upfront

    Merck secured global rights to preclinical oral KRAS G12D inhibitor SPR2015 through an exclusive licensing agreement with SciBrunch Therapeutics, a Shanghai small-molecule RAS startup. The deal includes a $400 million upfront payment and potential milestone payments up to $2.13 billion. The asset is a preclinical KRAS G12D(ON) molecular glue that has not yet been tested in humans.

    Why it matters

    This high-value deal highlights intense pharmaceutical interest in targeting specific cancer mutations, particularly as emerging clinical data reveal potential limitations for rival treatments across different mutation subtypes. KRAS inhibitors are being explored for their potential to treat various cancers. The licensing agreement underscores the growing importance of precision medicine in oncology.

    What is confirmed

    • Merck agreed to a $400 million upfront payment for the licensing deal.
    • The licensing agreement with SciBrunch Therapeutics includes potential milestone payments up to $2.13 billion.
    • Roche agreed to acquire Carmot Therapeutics for $2.7 billion upfront.
    • Carmot Therapeutics' pipeline includes three clinical-stage programmes.

    What to watch next

    • Merck's progress on the KRAS G12D inhibitor SPR2015
    • Roche's acquisition of Carmot Therapeutics and its impact on the obesity market
    • Future licensing deals for China-based companies
    Sources used for this update (4)
    1. pharmaphorum.com β€” Roche makes obesity play with $2.7bn deal to buy Carmot
    2. cdmohub.ai β€” China Drug Licensing Tracker: Edition 1 | CDMO Hub
    3. dealforma.com β€” Cancer R&D Partnerships, M&A, Venture Funding and IPO ...
    4. updates.biomednexus.com β€” Roche Pays Hansoh $400M Upfront to Rent Its ADC Platform
    confidence 90%
  2. Merck Acquires Preclinical KRAS G12D Drug From SciBrunch

    Merck secured global rights to the preclinical oral KRAS G12D inhibitor SPR2015 through an exclusive licensing agreement with SciBrunch Therapeutics, a two-year-old Shanghai small-molecule RAS startup. The transaction includes a $400 million upfront payment alongside potential milestone payments reaching up to $2.13 billion. The asset is a preclinical KRAS G12D(ON) molecular glue that has not yet been tested in humans. The high-value deal underscores intense pharmaceutical interest in targeting specific cancer mutations, particularly as emerging clinical data highlight potential limitations for rival treatments across different mutation subtypes.

    Why it matters

    The acquisition reflects a broader industry trend where major pharmaceutical firms invest heavily in early-stage Chinese drug discovery assets. Recent FDA review data concerning Revolution Medicines' pancreatic-cancer drug Rasonque showed weaker responses for the common G12D mutation compared to G12V. This clinical variation dropped rival shares by more than 6 percent and created an opening for competitors developing mutation-specific treatments.

    What is confirmed

    • Merck secured global rights to develop, manufacture, and commercialize the preclinical oral KRAS G12D inhibitor SPR2015 through an exclusive license agreement with SciBrunch Therapeutics.
    • The transaction carries a $400 million upfront payment alongside potential milestone payments reaching up to $2.13 billion.
    • SciBrunch Therapeutics is a Shanghai small-molecule RAS startup founded less than two years before licensing the asset.
    • FDA review data for Revolution Medicines' drug Rasonque showed responses were strongest for KRAS G12V, more modest for G12D, and weaker for G12R.

    Still unconfirmed

    • The deal signals desperation among Big Pharma companies regarding early-stage assets untested in humans.

    What to watch next

    • Human clinical trial filings and safety data for Merck and SciBrunch's SPR2015.
    • Further regulatory disclosures regarding KRAS G12D mutation-specific cancer therapies.
    Sources used for this update (6)
    1. www.biobucks.co β€” Biotech M&A Tracker 2026: 69 Acquisitions, ~$198.6B Tracked
    2. biotechmorning.com β€” Merck Just Paid $400M for a Cancer Drug That Hasn't Been ...
    3. squawknews.com β€” MRK - Merck & Co., Inc. News & Market Headlines - SquawkNews
    4. jimmyresearch.com β€” SciBrunch Therapeutics (ζ€η’žι”εŒ»θ―) β€” jimmyΒ·research
    5. www.biorichinc.com β€” BioLink Weekly | BioRich International
    6. www.talk.bio β€” Rasonque mutation-level data point to a possible opening for ...
    confidence 95%
  3. Merck Licenses Preclinical KRAS Inhibitor

    Merck secured global rights to develop, manufacture, and commercialize the preclinical oral KRAS G12D inhibitor SPR2015 through an exclusive license agreement with SciBrunch Therapeutics. The transaction carries a $400 million upfront payment, alongside potential milestone payments reaching up to $2.13 billion. Merck operates as Merck & Co., Inc. in the United States, Canada, and Puerto Rico, and as MSD elsewhere. The company ranks fifth among biomedical firms by revenue, driven heavily by cancer treatments like Keytruda, vaccines such as Gardasil, and animal health products.

    Why it matters

    The acquisition expands Merck's oncology pipeline into targeted KRAS inhibition, complementing its existing revenue reliance on blockbuster cancer therapies. Merck & Co. is a major American multinational pharmaceutical corporation headquartered in Rahway, New Jersey. The parent enterprise generates substantial earnings from oncology products, including billions annually from Keytruda sales.

    What is confirmed

    • Merck entered an exclusive global license agreement with SciBrunch Therapeutics for the preclinical oral KRAS G12D inhibitor SPR2015.
    • The licensing deal includes a $400 million upfront payment and potential milestone payments of up to $2.13 billion.
    • Merck holds worldwide rights to manufacture, develop, and commercialize the SPR2015 candidate.
    • Merck & Co., Inc. is headquartered in Rahway, New Jersey, and operates as MSD outside the United States and Canada.
    • Keytruda sales generated $29.5 billion in 2024, accounting for 46 percent of Merck's revenue.

    What to watch next

    • Progression of SPR2015 into clinical trials
    • Future milestone payments reported by Merck or SciBrunch Therapeutics
    Sources used for this update (7)
    1. www.merck.com β€” Merck | Home
    2. jobs.merck.com β€” Discover Job Opportunities at Merck | Merck Careers
    3. jobs.merck.com β€” Your job search results | Merck Careers
    4. www.merck.com β€” Contact us - Merck.com
    5. www.merck.com β€” Products list - Merck.com
    6. en.wikipedia.org β€” Merck & Co. - Wikipedia
    7. en.wikipedia.org β€” Merck Group - Wikipedia
    confidence 100%
  4. Merck licenses KRAS G12D inhibitor for $400M upfront

    Merck entered an exclusive global license agreement with SciBrunch Therapeutics for the preclinical oral KRAS G12D inhibitor SPR2015. The deal includes a $400 million upfront payment and potential payments of up to $2.13 billion through milestones. Merck now holds worldwide rights to manufacture, develop, and commercialize the candidate.

    Why it matters

    This deal expands Merck's precision targeted pipeline, focusing on one of the most common mutant forms of KRAS found in human cancers. KRAS inhibitors are a highly sought-after class of cancer therapeutics. The agreement was announced on September 28, 2026.

    What is confirmed

    • Merck & Co. entered an exclusive global license agreement with SciBrunch Therapeutics for SPR2015, a preclinical oral KRAS G12D inhibitor.
    • The deal includes a $400 million upfront payment and up to $2.13 billion in milestone payments.
    • Merck now holds worldwide rights to manufacture, develop, and commercialize SPR2015.
    • Merck & Co.'s stock was last at $144.30 on October 2, 2026.

    What to watch next

    • Merck's stock performance
    • Progress in SPR2015 development
    • Future deals in the KRAS inhibitor space
    Sources used for this update (6)
    1. www.biobucks.co β€” Biotech BD&L Tracker 2026: 156 Licensing & Partnering Deals
    2. www.ad-hoc-news.de β€” Merck & Co. stock gets a USD 400 million oncology bet
    3. www.ddw-online.com β€” MSD buys oral KRAS G12D (ON) inhibitor for $2.13 billion
    4. guavy.com β€” Merck Stock Dips 2.16 Percent Despite Positive Pipeline ...
    5. iswtcommunity.substack.com β€” A 5-Day 12.5-Billion East-West Deal Bonanza; China’s Three 5 ...
    6. www.p05.org β€” The Weekly Term Sheet (2026-W40)
    confidence 90%
  5. Merck licenses preclinical KRAS G12D inhibitor SPR2015 from SciBrunch

    Merck entered an exclusive global license agreement with Shanghai-based SciBrunch Therapeutics on September 28, 2026, to develop the preclinical oral KRAS G12D (ON) inhibitor SPR2015. The deal includes an upfront payment of $400 million and total potential payments reaching $2.13 billion through milestones. Merck now holds worldwide rights to manufacture, develop, and commercialize the candidate. The move expands Merck's precision targeted pipeline by focusing on one of the most common mutant forms of KRAS found in human cancers.

    Why it matters

    The KRAS pathway is a known driver of tumor cell growth. This acquisition follows the approval of Revolution Medicines' pancreatic cancer treatment, Rasonque, and places Merck in competition with other firms like Verastem Oncology and BridgeBio Oncology Therapeutics.

    What is confirmed

    • Merck paid SciBrunch Therapeutics $400 million upfront for the license.
    • The total value of the agreement can reach $2.13 billion.
    • SPR2015 is an investigational preclinical oral KRAS G12D (ON) inhibitor.
    • The agreement grants Merck exclusive worldwide rights to develop, manufacture, and commercialize SPR2015.
    • The deal was announced on September 28, 2026.
    • SciBrunch Therapeutics is based in China.

    Still unconfirmed

    • Merck stock slipped 1.5% following the announcement of the $400 million payment.
    • The deal follows a previous $24 million payment to the same founder for a different KRAS G12D drug.

    What to watch next

    • Transition of SPR2015 from preclinical stages to human clinical trials
    • Regulatory filings for SPR2015 with the FDA or other global health authorities
    Sources used for this update (16)
    1. endpoints.news β€” Merck licenses a KRAS G12D inhibitor for $400M upfront
    2. Reuters β€” Merck licenses SciBrunch cancer drug in deal worth up to $2.13 billion
    3. Fierce Biotech β€” Merck pens $2.1B deal with China’s SciBrunch to chase KRAS G12D
    4. Business Wire β€” Merck Enters into Exclusive Global License Agreement with SciBrunch Therapeutics for SPR2015, an Investigational Oral KRAS G12D (ON) Inhibitor
    5. BioSpace β€” Merck inks up to $2.13B deal to dine with SciBrunch, gain rights to preclinical KRAS inhibitor
    6. Reuters β€” US drugmakers turn to China for licensing deals
    7. www.pharmexec.com β€” Merck Licenses Preclinical KRAS G12D Inhibitor from SciBrunch
    8. www.merck.com β€” Merck Enters into Exclusive Global License Agreement with ...
    9. allsci.com β€” Merck strikes USD 2.13bn deal for China-origin preclinical ...
    10. www.fiercebiotech.com β€” Merck pens $2.1B deal with China’s SciBrunch to chase KRAS G12D
    11. guavy.com β€” Merck Licenses KRAS G12D Inhibitor SPR2015 for $400M Upfront
    12. medcitynews.com β€” Merck Pays $400M for Cancer Drug Prospect From China-Based ...
    confidence 100%
πŸ“Š

Community Sentiment: How do you assess this situation?

Voice your perspective Β· Real-time aggregated sentiment from the Live Feeds community